Click here to see a list of our past events.
Do you have a project in need of funding? Are you interested in learning about engaging with industry partners?
James Bellush, Manager of Scientific Scouting, will be hosting weekly virtual office hours, every Friday from 11 a.m. to 1 p.m. to help Weill Cornell investigators support their ongoing translational research projects through industry sponsored research collaborations and grants.
Please use the link here to schedule your private meeting with James. Questions? Email james.bellush@cornell.edu.
The BenDaniel Venture Challenge (BVC) is Big Red Venture’s Annual Pitch Competition. BRV will select five finalists to pitch their business ideas to a panel of investors during Entrepreneurship at Cornell Celebration on April 10. Winners will earn a cash prize totaling $25,000! Companies based in New York state or with a Cornell affiliation are eligible to apply. Big Red Ventures (BRV), Cornell’s early-stage venture capital fund, operated entirely by a team of MBA students, runs this competition each year, in partnership with Entrepreneurship at Cornell.
Application Deadline March 14th. Apply Here.
The following Virtual Courses are open to innovators in all STEM fields:
- March 30 – April 29: Apply by March 4.
- April 6 – May 6: Apply by March 11.
- April 13 – May 13: Open to startup/incubator teams. Apply by March 18.
- April 20 – May 20: Apply by March 25.
- June 1 – July 1: Apply by May 6.
Applications will be reviewed on a rolling basis. Apply now! Please contact icorps@cornell.edu for any questions.
Center for Technology Licensing (CTL) at Weill Cornell Medicine Office Hours are open to all who wish to gain more information about the advancement of their patent filings and to discuss their technology venture project in a one-on-one meeting with a business development and licensing professional. The March office hours will be hosted by Brian Kelly, Ph.D., CLP, director of business development and licensing.
Brian manages a portfolio of inventions focusing on oncology, gene therapy, metabolic diseases, the microbiome and endocrine disorders. Prior to joining CTL at Weill Cornell, he served as director of intellectual property for New York University’s tech transfer office. He has also held positions at the University of Minnesota as a licensing associate, Heide, Hyde & O’Donnell as an associate European patent attorney and Smith, Kline & French as a research chemist.
Register here for your 30-minute private session.
Ready to bring your product idea to life? – Apply Now.
The final application deadline is midnight (ET) on March 22, 2026.
Over 10 weeks, Rev’s Prototyping Hardware Accelerator offers four tracks – Classic, AgTech, ClimateTech and MedTech - to guide product teams to determine if their ideas are commercially desirable, technologically feasible and economically viable. Upon completion of the program, participants are positioned to recruit team members, bring on partners, initiate work with contract manufacturers and pitch to investors. Teams will receive a stipend of up to $2,000 to advance their prototype.
Register for an upcoming information session to have your questions answered by program leadership:
Questions about the program can be directed to rev@revithaca.com.
During this webinar, we will explore the role of business development and partnering in helping advance life sciences innovation from the lab to the marketplace. Through a discussion with our seasoned panelists, we will compare the business development objectives and strategies across different ecosystem partners (venture capital, biotech and pharma) and the role (and goals) of academic partnerships.
Why does health IT still frustrate so many healthcare stakeholders? Why were early systems designed with limited clinician input? Can AI help fix the problems created by legacy systems?
You’re invited to join us for a conversation with Dr. S. Yin Ho, author of Rushing Headlong: Health IT’s Legacy and the Road to Responsible AI.
In her new book, Dr. Ho examines how the early architecture of health information technology shaped the systems that clinicians and researchers struggle with today. As generative AI arrives, those same structural choices may determine whether AI ultimately better serves practitioners and patients or simply adds another layer of complexity.
Dr. Ho is a serial entrepreneur and visionary executive in health IT and clinical research with more than 25 years of experience founding, building, and leading healthcare technology companies and initiatives. Most recently, she served as Interim CEO of Veradigm, where she led the strategic acquisition of generative AI company ScienceIO. Under her leadership, Veradigm became the first electronic health record company to develop proprietary small language models in-house—an effort aimed at improving the quality of clinical data used for both care and research.
Join us for a candid discussion about the past, present, and future of health IT. Register here.
Participate in a free, month-long I-Corps Regional Course to receive expert guidance as you evaluate the market potential of your deep technology innovation. You’ll gain a deeper understanding of your field and learn valuable professional skills in the process.
In this conference course (May 11 - June 5), a select group of researchers working on oncology technology will "get out of their comfort zone" and talk to customers at the American Society of Clinical Oncology (ASCO) Annual Meeting to identify the best product-market fit. The course begins online and culminates with a trip to Chicago, IL for the 2026 ASCO Annual Meeting. Up to $5,000 (depending on team size) in travel reimbursement funding will be available for accepted teams*.
You may apply with a team of 1-3 people. Teams may not split attendance between members. Please only include the members of your team that will be fully participating in the course. All team members are required to attend and participate fully in every course session and complete all coursework.
Apply here. Applications will be reviewed on a rolling basis. Please contact icorps@cornell.edu for any questions.
Center for Technology Licensing (CTL) at Weill Cornell Medicine Office Hours are open to all who wish to gain more information about the advancement of their patent filings and to discuss their technology venture project with a one-on-one meeting with a Weill Cornell business development and licensing professional.
The Apr 21st office hours will be hosted by Eric Bryant, Intellectual Property Officer.
Eric holds a Master of Science in Biomedical Engineering from New York University (NYU), a Juris Doctor from New York Law School, and is a registered patent attorney. He works with the Weill Cornell office to execute on intellectual property strategy, review submitted invention disclosures, and manage domestic and foreign patent filings and patent prosecution.
His expertise encompasses a variety of technologies including, but not limited to, diagnostics tools and methods, pharmaceuticals, controlled release therapeutic devices, respiratory devices, surgical tools, biological technologies and nanotechnology.
Join our flagship ecosystem-building event, convening investors, industry representatives, entrepreneurs and academic innovators/spinouts.
The 2026 Weill Cornell Medicine BioInnovate Conference brings together academic founders with investors, industry representatives, entrepreneurs and ecosystem partners with the expressed goal to connect and collaborate. The conference is a rare opportunity to meet a diverse group of life science inventors and spinout companies across therapeutics, device, digital health and diagnostic sectors. All Weill Cornell Medicine-affiliated inventors are encouraged to participate. In addition, select startup companies from the Upper East Side ecosystem as well as startups where faculty serve as CMOs and scientific advisors are also in attendance.
Over the years, this event has been a proven catalyst for direct investment from early-stage investors, co-development relationships with industry, and introductions to experienced management teams.
This exciting program is for Principal Investigators who are employed full-time by Weill Cornell Medicine. Tri-I TDI partners with Takeda Pharmaceuticals to advance early-stage projects, that have the potential to benefit patients, to proof-of-concept studies.
The program’s objective is to develop novel compounds that elucidate fundamental physiologic and pathological processes, improve efficiency in drug development, create intellectual property that can be further developed by industry collaborators, and translate basic research into clinical application.
Only small molecule chemical compounds will be considered, which excludes antibody, protein and any other biologic therapeutics.
Log into your VPN to access the application page for more details and application process: https://intranet.tritdi.org/applications/small-molecules/.
